| USGOV-DEPARTMENT-OF-DEFENSE |
USGOV-DEPARTMENT-OF-DEFENSE |
95%
|
USAspending awards from Department of Defense: $11,111,678,908 across 5 awards. W15QKN21C0012 COVID-19 VACCINE PRODUCTION; SPE2D025F0634 8511599130!OTHER MEDICAL; SPE2D023F0609 8510100624!OTHER MEDIC… |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES |
95%
|
USAspending awards from Department of Health and Human Services: $74,372,673 across 5 awards. HHSO100201500029C IGF::OT::IGF; 75A50324F80014 THE PURPOSE OF THIS DELIVERY ORDER IS TO PROCURE PHARMACEU… |
| ALLO |
Allogene Therapeutics, Inc. |
92%
|
Reciprocal relationship from ALLO graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ALLO graph: In April 2018, the Company entered into an Asset Contribution Agreement (the … |
| ARVN |
Arvinas, Inc. |
92%
|
Reciprocal relationship from ARVN graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ARVN graph: In July 2021, Arvinas announced a global collaboration with Pfizer for the co… |
| CCCC |
C4 Therapeutics, Inc. |
92%
|
Reciprocal relationship from CCCC graph: Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial Dexamethasone (dex) |
| CELC |
Celcuity Inc. |
92%
|
Reciprocal relationship from CELC graph: The Company entered into a license agreement with Pfizer to research, develop, manufacture and commercialize gedatolisib. |
| ITRM |
Iterum Therapeutics PLC |
92%
|
Reciprocal relationship from ITRM graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ITRM graph: In November 2015, we and our wholly owned subsidiary, Iterum Therapeutics Int… |
| PYXS |
Pyxis Oncology, Inc. |
92%
|
Reciprocal relationship from PYXS graph: Reciprocal relationship from PFE graph: Reciprocal relationship from PYXS graph: Pfizer granted to the Company exclusive worldwide rights under Pfizer's Flexi… |
| AURX |
Nuo Therapeutics, Inc. |
90%
|
Reciprocal relationship from AURX graph: a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an existing supply agreement |
| ESPR |
Esperion Therapeutics, Inc. |
90%
|
Reciprocal relationship from ESPR graph: In April 2008, we entered into an asset transfer agreement with Pfizer pursuant to which we acquired all intellectual property owned by Pfizer relating exclus… |
| ZURA |
Zura Bio Limited |
90%
|
Reciprocal relationship from ZURA graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ZURA graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ZURA gra… |
| GOVERNMENTS |
GOVERNMENTS |
80%
|
For additional information on our trade accounts receivables with significant customers, see Note 17C in our 2025 Form 10-K. |
| WHOLESALERS |
WHOLESALERS |
80%
|
For additional information on our trade accounts receivables with significant customers, see Note 17C in our 2025 Form 10-K. |
| CAH |
Cardinal Health, Inc. |
72%
|
ed with sales recorded in 2022, related to the expected return of an estimated million treatment courses of EUA-labeled U.S. government inventory. In the first quarter of 2024, we recorded a non-cash… |
| CAH |
Cardinal Health, Inc. |
72%
|
Reciprocal relationship from CAH graph: Reciprocal relationship from PFE graph: Reciprocal relationship from CAH graph: Reciprocal relationship from PFE graph: ed with sales recorded in 2022, related… |
| OPK |
OPKO Health, Inc. |
72%
|
Reciprocal relationship from OPK graph: Reciprocal relationship from PFE graph: Reciprocal relationship from OPK graph: Reciprocal relationship from PFE graph: Reciprocal relationship from OPK graph:… |
| OPK |
OPKO Health, Inc. |
72%
|
. We promote our products to healthcare providers and patients consistent with applicable laws. Through our marketing organizations, we explain the approved uses, benefits and risks of our products t… |
| ZLAB |
Zai Lab Limited |
72%
|
Item 1A. Risk Factors—Research and Development section. COLLABORATION AND CO-PROMOTION AGREEMENTS We use collaboration and/or co-promotion arrangements to enhance our R&D, sales and distribution of c… |
| ZLAB |
Zai Lab Limited |
72%
|
Reciprocal relationship from ZLAB graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from PFE graph: Item 1A. Risk Factors—Research and De… |
| CTMX |
CytomX Therapeutics, Inc. |
70%
|
Reciprocal relationship from CTMX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from CTMX gra… |
| FINANCIAL-CONDITION-LIQUIDITY-CAPITAL-RESOURCES |
FINANCIAL-CONDITION-LIQUIDITY-CAPITAL-RESOURCES |
62%
|
or adequate pricing or favorable formulary placement for our products; • interest rate and foreign currency exchange rate fluctuations, including the impact of global trade tensions, as well as curre… |
| IMCLONE-LLC |
IMCLONE-LLC |
62%
|
folio. (f) Primarily reflects Alliance revenues and royalty revenues. (g) Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily inclu… |
| MD-A-PFIZER-INC |
MD-A-PFIZER-INC |
62%
|
Item 1A. Risk Factors—Research and Development section. COLLABORATION AND CO-PROMOTION AGREEMENTS We use collaboration and/or co-promotion arrangements to enhance our development, R&D, sales and dist… |
| MORE-FOCUSED-COMPANY |
MORE-FOCUSED-COMPANY |
62%
|
emium paid on our equity investment in Acquired in-process research and development expenses . In October 2022, we acquired all outstanding common shares of Biohaven not already owned by us for $ 148… |
| OTHER-PAYOR-GROUP |
OTHER-PAYOR-GROUP |
62%
|
iii) increases in Cost of sales and Research and development expenses. See the Analysis of the Condensed Consolidated Statements of Operations section within MD&A and Notes 3 and 4 . For information … |
| FRANCE |
FRANCE |
60%
|
As of March 29, 2026, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., the U.K., … |
| JAPAN |
JAPAN |
60%
|
As of March 29, 2026, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., the U.K., … |
| PFIZER-IGNITE-OPERATING-SEGMENT |
PFIZER-IGNITE-OPERATING-SEGMENT |
60%
|
Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in both periods presented. |
| SWEDEN |
SWEDEN |
60%
|
As of March 29, 2026, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., the U.K., … |
| U-K |
U-K |
60%
|
As of March 29, 2026, the largest investment exposures in our portfolio consisted primarily of U.S. government money market funds, as well as sovereign debt instruments issued by the U.S., the U.K., … |
